<PAGE>
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 31, 2000
THE COOPER COMPANIES, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<CAPTION>
<S> <C> <C>
Delaware 1-8597 94-2657368
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)
</TABLE>
6140 Stoneridge Mall Road, Suite 590, Pleasanton, California 94588
(Address of principal executive offices)
(925) 460-3600
(Registrant's telephone number, including area code)
================================================================================
<PAGE>
ITEM 5. OTHER EVENTS.
On January 31, 2000, The Cooper Companies, Inc. issued a press release
announcing that its CooperSurgical unit completed the purchase of a group of
women's healthcare products from Leisegang Medical, Inc. This release is filed
as an exhibit hereto and is incorporated by reference herein.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
Exhibit
No. Description
- ------- -----------
99.1 Press Release dated January 31, 2000 of The Cooper Companies, Inc.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE COOPER COMPANIES, INC.
By /s/ Stephen C. Whiteford
------------------------
Stephen C. Whiteford
Vice President and
Corporate Controller
(Principal Accounting Officer)
Dated: February 2, 2000
<PAGE>
EXHIBIT INDEX
Exhibit Sequentially
No. Description Numbered Page
- ------- ----------- -------------
99.1 Press Release dated January 31, 2000 of The Cooper
Companies, Inc.
<PAGE>
[LOGO OMITTED] THE COOPER COMPANIES
[LOGO OMITTED]
NEWS RELEASE
CONTACT:
NORRIS BATTIN
THE COOPER COMPANIES, INC.
[email protected]
COOPER COMPANIES' UNIT COMPLETES ACQUISITION OF LEISEGANG WOMEN'S
HEALTHCARE PRODUCTS
IRVINE, Calif., January 31, 2000 - The Cooper Companies, Inc. (NYSE/PCX: COO)
announced today that its CooperSurgical (CSI) women's healthcare unit has
completed the purchase of a group of women's healthcare products from Leisegang
Medical, Inc. for approximately $10.5 million in cash. The products currently
generate annual revenue in excess of $11 million. Cooper expects the transaction
to be accretive to fiscal 2000 earnings. Leisegang is a subsidiary of NetOptix
Corporation (NASDAQ: OPTX).
Leisegang is a well-known and highly regarded women's healthcare company. It
markets diagnostic and surgical instruments including colposcopes, instruments
to perform loop electrosurgical excision procedures, hand held gynecological
instruments, disposable specula and cryosurgical systems. Many of its products
are disposable, including its Sani-Spec(R) line of disposable plastic specula,
its largest product group. The acquisition will expand CSI's global presence, as
it plans to market its line of gynecological products through Leisegang's German
subsidiary.
In December 1999, CSI announced that it had completed the acquisition of a line
of women's healthcare products from BEI medical Systems. CSI's annual revenue
will exceed $50 million in calendar year 2000 with the addition of these new
product lines.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. To identify forward-looking
statements, look for words like "believes," "expects," "may," "will," "should,"
"seeks," "approximately," "intends," "plans," "estimates" or "anticipates" and
similar words or phrases. Discussions of strategy, plans or intentions often
contain forward-looking statements. These, and all forward-looking statements,
necessarily depend on assumptions, data or methods that may be incorrect or
imprecise.
<PAGE>
Events, among others, that could cause actual results and future actions to
differ materially from those described by or contemplated in the forward-looking
statements include major changes in business conditions and the economy, loss of
key senior management, major disruptions in the operations of Cooper's
manufacturing facilities, new competitors or technologies, significant
disruptions caused by third parties failing to address the year 2000 issue, or
by problems with our year 2000 compliance program, the impact of an undetected
virus on our computer system, acquisition integration costs, foreign currency
exchange exposure, investments in research and development and other start-up
projects, dilution to earnings per share from acquisitions or issuing stock,
regulatory issues, significant environmental cleanup costs above those already
accrued, litigation costs, costs of business divestitures, and other factors
described in Cooper's Securities and Exchange Commission filings, including the
"Business" section in our Annual Report on Form 10-K for the year ended October
31, 1999.
Cooper cautions investors not to rely unduly on forward-looking statements. They
reflect our analysis only on their stated date or the date of this press
release.
The Cooper Companies, Inc. and its subsidiaries develop, manufacture and market
specialty healthcare products. CooperSurgical, Inc., headquartered in Shelton,
Conn., markets diagnostic products, surgical instruments and accessories for the
gynecological market. CooperVision, Inc., headquartered in Irvine, Calif., with
manufacturing facilities in Huntington Beach, Calif., Rochester, N.Y., Toronto,
Canada and Hamble, England, markets a broad range of contact lenses for the
vision care market. Corporate offices are located in Irvine and Pleasanton,
Calif. A toll free interactive telephone system at 1-800-334-1986 provides stock
quotes, recent press releases and financial data. Cooper's web address is
www.coopercos.com.
